Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Mol Nutr Food Res ; 60(4): 823-33, 2016 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-26719048

RESUMO

SCOPE: ß-casofensin, also known as peptide ß-CN(94-123), is a milk bioactive peptide that modulates the intestinal barrier through its action on goblet cells. Here, we evaluated whether oral administration of ß-casofensin can prevent indomethacin-induced injury of the jejunum in rats. METHODS AND RESULTS: Rats received ß-casofensin (0.01-100 µM) or tap water by daily gavage (4 µL/g) for eight days, then two subcutaneous injections of indomethacin (10 mg/kg, days 9 and 10) and were euthanized on day 12. In vitro, we investigated the effects of ß-casofensin on the restitution of a wounded monolayer. Preventive administration of ß-casofensin (100 µM) reduced intestinal macroscopic and microscopic damage induced by indomethacin. ß-casofensin also prevented the depletion of goblet cells and increased myeloperoxidase activity, as well as tumor necrosis factor-ɑ (TNF-ɑ) expression and immunostaining of active caspase-3 in the jejunum of rats treated with indomethacin. In wound healing experiments, ß-casofensin promoted epithelial restitution with no effect on cell proliferation. This effect was inhibited by pre-incubation with an anti-CC chemokine receptor 6 (CCR6) neutralizing antibody. CONCLUSIONS: ß-casofensin exerts protective effects in indomethacin-induced enteritis through preservation of goblet cells and improvement in wound healing. ß-casofensin could therefore become vital in nutritional programs for the prevention of intestinal diseases.


Assuntos
Caseínas/química , Caseínas/farmacologia , Indometacina/efeitos adversos , Intestinos/efeitos dos fármacos , Fragmentos de Peptídeos/farmacologia , Cicatrização/efeitos dos fármacos , Administração Oral , Animais , Bovinos , Enterite/induzido quimicamente , Enterite/prevenção & controle , Células HT29/efeitos dos fármacos , Humanos , Mucosa Intestinal/efeitos dos fármacos , Mucosa Intestinal/patologia , Intestinos/patologia , Doenças do Jejuno/induzido quimicamente , Doenças do Jejuno/prevenção & controle , Masculino , Fragmentos de Peptídeos/administração & dosagem , Fragmentos de Peptídeos/química , Substâncias Protetoras/farmacologia , Ratos Wistar
SELEÇÃO DE REFERÊNCIAS
Detalhe da pesquisa